(Date:1/9/2009)..., Fla. -- A unique discovery in a Florida State Un...is for research with the potential to one day help...eases in the tissue where they are forming. , Ja...iences at the College of Medicine, has received a ...stitutes of Health to pursue her work. Horabin rec...
(Date:1/9/2009)... Blackbaud, Inc. today announced that it...ndation of Canada that will create a unified natio... Charleston, S.C. (Vocus) January 9, 2009 -- Bla... it will develop a custom solution for The Kidney ...tional CRM and web presence., , , , ,"We sel...
(Date:1/9/2009)...HIA) Efforts to fight the toll of cardiac arrest ...bystander CPR education and improvement, public de...ut new research from the University of Pennsylvani...re patients are cared for after being resuscitated...lowing these incidents, which takes the lives of m...
(Date:1/9/2009)... Use It As Both a Membership Card and Debit Card f... 9 UPMC Health Plan eliminates the...Flexible Spending Account (FSA) with its new My F...to Western Pennsylvania - serves as both a health ...t-of-pocket health care expenses. , , The My F...
Breaking Medicine News(10 mins):Health News:Researcher wins $1.2 million grant for gene regulation work 2Health News:Blackbaud to Deliver National CRM Database and Bilingual Website for The Kidney Foundation of Canada 2Health News:Blackbaud to Deliver National CRM Database and Bilingual Website for The Kidney Foundation of Canada 3Health News:Blackbaud to Deliver National CRM Database and Bilingual Website for The Kidney Foundation of Canada 4Health News:Penn study: Chances of surviving cardiac arrest depend on where patients are treated 2Health News:Penn study: Chances of surviving cardiac arrest depend on where patients are treated 3Health News:UPMC Health Plan Introduces `MyFlex Advantage' Card 2Health News:UPMC Health Plan Introduces `MyFlex Advantage' Card 3...erala as an ideal destination for medical tourism,...ad shows in the US, Britain, Dubai, Muscat, Kuwait...red for this because it has to be systematic and w...f Indian Industries) to give inputs to the draft o...
...rofessor of medicine and physiology and director o...rch at McGill University in Montreal//, and collea...levant in geriatric medicine and psychiatry. Eld...ti-depressants regularly run a risk of increased f...
...niversity of Illinois at Urbana-Champaign have com...hod // that is used for optical microscopy, which ...images from hazy and unclear data. The technique,...ure Microscopy, ISAM is beneficial to optical micr...
...ts of a deadly superbug that attacks healthy young... is a vital first step in attempts to find a cure ... resistant to current antibiotic treatments. Alr...aths in Britain, experts fear we are in the early ...
Other Medicine News:Health News:Prozac-popping Elders at Higher Risk of Fractures 2Health News:New Computed Imaging Technique Uses Hazy Images to Improve View 2(Date:1/8/2009)..., CHICAGO, Jan. 8 If you are ...t today, you,re not alone. Half of the people taki...bed. The reasons are,varied -- they forget, are b...cision not to. Noncompliance has been called the A...eon General Everett Koop commented, "Drugs don,t,...
(Date:1/7/2009)..., INDIANAPOLIS, Jan. 7 /PRNewswire-FirstCall/...d today that it received a complete response lette...) for olanzapine long-acting,injection (LAI) for ...n,adults. Lilly is continuing to work with the ag...The FDA does not require any additional clinical t...
(Date:1/7/2009)..., FREDERICK, Md., Jan. 7 ImQuest ...ssion of an IND application to the Food and Drug A...r their lead pyrimidinedione HIV inhibitor IQP-041...udies in the first quarter of 2009. IQP-0410 is a ...ily acts as a nonnucleoside reverse transcriptase ...
(Date:1/7/2009)..., OXFORD, England, January 7 ...any focused on allergy and critical care, today,a...s achieved in 2008 with,its ToleroMune(R) anti-al...atient recruitment for a further phase II clinical...ay in Canada, has recruited 120 patients with conf...
Breaking Medicine Technology:Good Medicine: Smarter Smartphones for People With Chronic Disease 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease 2290 1AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease 2290 2AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease 2290 3AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease 2290 4iNOS expression may links chronic biliary inflammation to malignant transformation 8523 1iNOS expression may links chronic biliary inflammation to malignant transformation 8523 2Scripps Research discovery leads to broad potential applications in CovX Pfizer deal 1667 1Scripps Research discovery leads to broad potential applications in CovX Pfizer deal 1667 2Scripps Research discovery leads to broad potential applications in CovX Pfizer deal 1667 3Scripps Research discovery leads to broad potential applications in CovX Pfizer deal 1667 4Scripps Research discovery leads to broad potential applications in CovX Pfizer deal 1667 5Enuresis Treatment Center Makes Summer Camp a Reality for Bedwetters 8517 1Enuresis Treatment Center Makes Summer Camp a Reality for Bedwetters 8517 2...FirstCall/ -- VION,PHARMACEUTICALS, INC. announced...er session at the 43rd Annual Meeting of The Ameri...d anticancer agent,Cloretazine(R) (VNP40101M) as a... relapsed or refractory small cell lung cancer. , ...101M) in two,separate subpopulations of small cell...
...rstCall/ -- BSD,Medical Corp. announced today that... clinical trial testing the benefit of adding,hype... the annual,American Society of Clinical Oncology ...ccording to the results of this clinical study,wh...eatment,institutions and at Duke University Medica...
Other Medicine Technology:Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 2Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 3Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 4Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival,Compared to Chemotherapy Alone for Sarcoma Cancer Patients 2Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival,Compared to Chemotherapy Alone for Sarcoma Cancer Patients 3Sera available in three levels for the control of accuracy and precision for up to 31 analytes
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes.
CRP Liquid Conrtols level 2
The AST method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma
Medicine Products: